IMPORTANCE: Blinatumomab is a CD3/CD19-directed bispecific T-cell engager molecule with efficacy in children with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). OBJECTIVE: To evaluate event-free survival in children with high-risk first-relapse B-ALL after a third consolidation course with blinatumomab vs consolidation chemotherapy before allogeneic hematopoietic stem cell transplant. DESIGN, SETTING, AND PARTICIPANTS: In this randomized phase 3 clinical trial, patients were enrolled November 2015 to July 2019 (data cutoff, July 17, 2019). Investigators at 47 centers in 13 countries enrolled children older than 28 days and younger than 18 years with high-risk first-relapse B-ALL in morphologic complete remission (M1 marrow, <5% blasts) or with M2 marrow (blasts ≥5% and <25%) at randomization. INTERVENTION: Patients were randomized to receive 1 cycle of blinatumomab (n = 54; 15 μg/m2/d for 4 weeks, continuous intravenous infusion) or chemotherapy (n = 54) for the third consolidation. MAIN OUTCOMES AND MEASURES: The primary end point was event-free survival (events: relapse, death, second malignancy, or failure to achieve complete remission). The key secondary efficacy end point was overall survival. Other secondary end points included minimal residual disease remission and incidence of adverse events. RESULTS: A total of 108 patients were randomized (median age, 5.0 years [interquartile range {IQR}, 4.0-10.5]; 51.9% girls; 97.2% M1 marrow) and all patients were included in the analysis. Enrollment was terminated early for benefit of blinatumomab in accordance with a prespecified stopping rule. After a median of 22.4 months of follow-up (IQR, 8.1-34.2), the incidence of events in the blinatumomab vs consolidation chemotherapy groups was 31% vs 57% (log-rank P < .001; hazard ratio [HR], 0.33 [95% CI, 0.18-0.61]). Deaths occurred in 8 patients (14.8%) in the blinatumomab group and 16 (29.6%) in the consolidation chemotherapy group. The overall survival HR was 0.43 (95% CI, 0.18-1.01). Minimal residual disease remission was observed in more patients in the blinatumomab vs consolidation chemotherapy group (90% [44/49] vs 54% [26/48]; difference, 35.6% [95% CI, 15.6%-52.5%]). No fatal adverse events were reported. In the blinatumomab vs consolidation chemotherapy group, the incidence of serious adverse events was 24.1% vs 43.1%, respectively, and the incidence of adverse events greater than or equal to grade 3 was 57.4% vs 82.4%. Adverse events leading to treatment discontinuation were reported in 2 patients in the blinatumomab group. CONCLUSIONS AND RELEVANCE: Among children with high-risk first-relapse B-ALL, treatment with 1 cycle of blinatumomab compared with standard intensive multidrug chemotherapy before allogeneic hematopoietic stem cell transplant resulted in an improved event-free survival at a median of 22.4 months of follow-up. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02393859.

Amgen Inc Thousand Oaks California

Amgen Ltd Uxbridge United Kingdom

Amgen Research Munich Germany

Azienda Ospedaliera di Rilievo Nazionale Santobono Pausilipon Naples Italy

Charité Universitätsmedizin Berlin Berlin Germany

Charles University Motol University Hospital Prague Czech Republic

IRCCS Istituto Giannina Gaslini Genova Italy

IRCCS Ospedale Pediatrico Bambino Gesù and Sapienza University of Rome Rome Italy

Jena University Hospital Jena Germany

Medizinische Hochschule Hannover Hannover Germany

Sorbonne Université Hôpital Armand Trousseau AP HP Paris France

St Anna Children's Hospital Vienna Austria

Tata Translational Cancer Research Center Tata Medical Center Kolkata West Bengal India

The University of Manchester Manchester United Kingdom

Universitätsklinikum Frankfurt am Main Frankfurt Germany

Universitätsklinikum Freiburg Freiburg Germany

Universitätsklinikum Schleswig Holstein Kiel Germany

University of Milano Bicocca MBBM Foundation Monza Italy

Westmead Hospital Sydney New South Wales Australia

JAMA. 2021 Mar 2;325(9):830-832. doi: 10.1001/jama.2021.1395. PubMed

JAMA. 2021 Jul 27;326(4):359. doi: 10.1001/jama.2021.8151. PubMed

JAMA. 2021 Oct 19;326(15):1524-1525. doi: 10.1001/jama.2021.10174. PubMed

Zobrazit více v PubMed

Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373(16):1541-1552. doi:10.1056/NEJMra1400972 PubMed DOI

Irving JA, Enshaei A, Parker CA, et al. . Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia. Blood. 2016;128(7):911-922. doi:10.1182/blood-2016-03-704973 PubMed DOI PMC

Krentz S, Hof J, Mendioroz A, et al. . Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia. Leukemia. 2013;27(2):295-304. doi:10.1038/leu.2012.155 PubMed DOI

Malempati S, Gaynon PS, Sather H, La MK, Stork LC; Children’s Oncology Group . Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children’s Oncology Group study CCG-1952. J Clin Oncol. 2007;25(36):5800-5807. doi:10.1200/JCO.2007.10.7508 PubMed DOI

Locatelli F, Schrappe M, Bernardo ME, Rutella S. How I treat relapsed childhood acute lymphoblastic leukemia. Blood. 2012;120(14):2807-2816. doi:10.1182/blood-2012-02-265884 PubMed DOI

Peters C, Schrappe M, von Stackelberg A, et al. . Stem-cell transplantation in children with acute lymphoblastic leukemia: a prospective international multicenter trial comparing sibling donors with matched unrelated donors: the ALL-SCT-BFM-2003 trial. J Clin Oncol. 2015;33(11):1265-1274. doi:10.1200/JCO.2014.58.9747 PubMed DOI

Bargou R, Leo E, Zugmaier G, et al. . Tumor regression in cancer patients by very low doses of a T cell–engaging antibody. Science. 2008;321(5891):974-977. doi:10.1126/science.1158545 PubMed DOI

von Stackelberg A, Locatelli F, Zugmaier G, et al. . Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. J Clin Oncol. 2016;34(36):4381-4389. doi:10.1200/JCO.2016.67.3301 PubMed DOI

Gökbuget N, Dombret H, Bonifacio M, et al. . Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131(14):1522-1531. doi:10.1182/blood-2017-08-798322 PubMed DOI PMC

Locatelli F, Zugmaier G, Mergen N, et al. . Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study. Blood Cancer J. 2020;10(7):77. doi:10.1038/s41408-020-00342-x PubMed DOI PMC

Eckert C, Henze G, Seeger K, et al. . Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group. J Clin Oncol. 2013;31(21):2736-2742. doi:10.1200/JCO.2012.48.5680 PubMed DOI

Parker C, Waters R, Leighton C, et al. . Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet. 2010;376(9757):2009-2017. doi:10.1016/S0140-6736(10)62002-8 PubMed DOI PMC

Paganin M, Zecca M, Fabbri G, et al. . Minimal residual disease is an important predictive factor of outcome in children with relapsed “high-risk” acute lymphoblastic leukemia. Leukemia. 2008;22(12):2193-2200. doi:10.1038/leu.2008.227 PubMed DOI

Domenech C, Mercier M, Plouvier E, et al. . First isolated extramedullary relapse in children with B-cell precursor acute lymphoblastic leukaemia: results of the Cooprall-97 study. Eur J Cancer. 2008;44(16):2461-2469. doi:10.1016/j.ejca.2008.08.007 PubMed DOI

Charité–University Hospital of Berlin . International study for treatment of standard risk childhood relapsed ALL. Accessed February 1, 2021. https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000793-30

Möricke A, Zimmermann M, Valsecchi MG, et al. . Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. Blood. 2016;127(17):2101-2112. doi:10.1182/blood-2015-09-670729 PubMed DOI

van der Velden VH, Cazzaniga G, Schrauder A, et al. ; European Study Group on MRD Detection in ALL (ESG-MRD-ALL) . Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia. 2007;21(4):604-611. doi:10.1038/sj.leu.2404586 PubMed DOI

Mejstríková E, Hrusak O, Borowitz MJ, et al. . CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment. Blood Cancer J. 2017;7(12):659. doi:10.1038/s41408-017-0023-x PubMed DOI PMC

Brüggemann M, Gökbuget N, Kneba M. Acute lymphoblastic leukemia: monitoring minimal residual disease as a therapeutic principle. Semin Oncol. 2012;39(1):47-57. doi:10.1053/j.seminoncol.2011.11.009 PubMed DOI

Brüggemann M, Schrauder A, Raff T, et al. ; European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL); International Berlin-Frankfurt-Münster Study Group (I-BFM-SG) . Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia. 2010;24(3):521-535. doi:10.1038/leu.2009.268 PubMed DOI

Tallen G, Ratei R, Mann G, et al. . Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J Clin Oncol. 2010;28(14):2339-2347. doi:10.1200/JCO.2009.25.1983 PubMed DOI

Handgretinger R, Zugmaier G, Henze G, Kreyenberg H, Lang P, von Stackelberg A. Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia. Leukemia. 2011;25(1):181-184. doi:10.1038/leu.2010.239 PubMed DOI

Topp MS, Kufer P, Gökbuget N, et al. . Targeted therapy with the T-cell–engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29(18):2493-2498. doi:10.1200/JCO.2010.32.7270 PubMed DOI

O’Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35(3):549-556. doi:10.2307/2530245 PubMed DOI

Gordon Lan KK, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika. 1983;70:659-663. doi:10.1093/biomet/70.3.659 DOI

Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496-509. doi:10.1080/01621459.1999.10474144 DOI

Branson M, Whitehead J. Estimating a treatment effect in survival studies in which patients switch treatment. Stat Med. 2002;21(17):2449-2463. doi:10.1002/sim.1219 PubMed DOI

Lansky SB, List MA, Lansky LL, Ritter-Sterr C, Miller DR. The measurement of performance in childhood cancer patients. Cancer. 1987;60(7):1651-1656. doi:10.1002/1097-0142(19871001)60:7<1651::AID-CNCR2820600738>3.0.CO;2-J PubMed DOI

Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol. 1984;2(3):187-193. doi:10.1200/JCO.1984.2.3.187 PubMed DOI

Bader P, Kreyenberg H, Henze GH, et al. ; ALL-REZ BFM Study Group . Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J Clin Oncol. 2009;27(3):377-384. doi:10.1200/JCO.2008.17.6065 PubMed DOI

Ruggeri A, Michel G, Dalle JH, et al. . Impact of pretransplant minimal residual disease after cord blood transplantation for childhood acute lymphoblastic leukemia in remission: an Eurocord, PDWP-EBMT analysis. Leukemia. 2012;26(12):2455-2461. doi:10.1038/leu.2012.123 PubMed DOI

Cooper SL, Brown PA. Treatment of pediatric acute lymphoblastic leukemia. Pediatr Clin North Am. 2015;62(1):61-73. doi:10.1016/j.pcl.2014.09.006 PubMed DOI PMC

Mouttet B, Vinti L, Ancliff P, et al. . Durable remissions in TCF3-HLF positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantation. Haematologica. 2019;104(6):e244-e247. doi:10.3324/haematol.2018.210104 PubMed DOI PMC

Forero-Castro M, Montaño A, Robledo C, et al. . Integrated genomic analysis of chromosomal alterations and mutations in B-cell acute lymphoblastic leukemia reveals distinct genetic profiles at relapse. Diagnostics. 2020;10(7):455. doi:10.3390/diagnostics10070455 PubMed DOI PMC

Schmiegelow K, Attarbaschi A, Barzilai S, et al. ; Ponte di Legno Toxicity Working Group . Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus. Lancet Oncol. 2016;17(6):e231-e239. doi:10.1016/S1470-2045(16)30035-3 PubMed DOI

Stein AS, Schiller G, Benjamin R, et al. . Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors. Ann Hematol. 2019;98(1):159-167. doi:10.1007/s00277-018-3497-0 PubMed DOI PMC

Kantarjian H, Stein A, Gökbuget N, et al. . Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836-847. doi:10.1056/NEJMoa1609783 PubMed DOI PMC

Martinelli G, Boissel N, Chevallier P, et al. . Complete hematologic and molecular response in adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. J Clin Oncol. 2017;35(16):1795-1802. doi:10.1200/JCO.2016.69.3531 PubMed DOI

Brown PA, Ji L, Xu X, et al. . A randomized phase 3 trial of blinatumomab vs chemotherapy as post-reinduction therapy in high and intermediate risk (HR/IR) first relapse of B-acute lymphoblastic leukemia (B-ALL) in children and adolescents/young adults (AYAs) demonstrates superior efficacy and tolerability of blinatumomab: a report from Children's Oncology Group Study AALL1331. Blood. 2019;134(suppl 2):LBA-1. doi:10.1182/blood-2019-132435 DOI

Maude SL, Frey N, Shaw PA, et al. . Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507-1517. doi:10.1056/NEJMoa1407222 PubMed DOI PMC

Curran KJ, Margossian SP, Kernan NA, et al. . Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL. Blood. 2019;134(26):2361-2368. doi:10.1182/blood.2019001641 PubMed DOI PMC

Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL

The EHA Research Roadmap: Malignant Lymphoid Diseases

Other (Non-CNS/Testicular) Extramedullary Localizations of Childhood Relapsed Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma-A Report from the ALL-REZ Study Group

Zobrazit více v PubMed

ClinicalTrials.gov
NCT02393859